TAPP is designed to:
- Ensure that those patients most likely to benefit from treatment receive TYSABRI.
- Assist neurologists to appropriately assess the benefit/risk balance for each of their patients.
- Ensure that TYSABRI is discontinued earlier rather than later if symptoms and/or signs appear consistent with PML.
TAPP consists of:
- Neurologist and Infusion Nurses - compulsory prescribing program.
- All Australian trained Healthcare Professionals to be recorded in a dedicated database (TAPP database) as per TGA reporting requirements.
- Safety Updates and educational resources including:
TYSABRI Approved Product Information;
TYSABRI Consumer Medicine Information;
TYSABRI PBS Authority Information;
Process for requesting various medical tests for TYSABRI patients (anti-JCV antibody, anti-natalizumab antibody,
JC Viral DNA testing)PML Identification and Response brochure
